RYTM
Closed
Rhythm Pharmaceuticals Inc
65.44
+2.25 (+3.56%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 63.19
Day's Range: 62.835 - 66.21
Send
sign up or login to leave a comment!
When Written:
18.09
Rhythm Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and commercialization of therapies for rare genetic diseases of obesity. The company was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm's lead product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor (MC4R) agonist being developed for the treatment of rare genetic disorders of obesity, including Bardet-Biedl syndrome (BBS) and Alström syndrome, as well as other MC4R-related obesity disorders. The company's mission is to improve the lives of people living with rare genetic disorders of obesity by developing and delivering innovative therapies. Rhythm is committed to advancing the understanding of the genetic causes of obesity and to developing treatments that address the underlying biology of these disorders.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








